Cargando…
Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy
Histone DeACetylases (HDACs) are enzymes that remove acetyl groups from histones and other proteins, regulating the expression of target genes. Pharmacological inhibition of these enzymes re-shapes chromatin acetylation status, confusing boundaries between transcriptionally active and quiescent chro...
Autores principales: | Manzotti, Gloria, Ciarrocchi, Alessia, Sancisi, Valentina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468908/ https://www.ncbi.nlm.nih.gov/pubmed/30841549 http://dx.doi.org/10.3390/cancers11030304 |
Ejemplares similares
-
HDACs control RUNX2 expression in cancer cells through redundant and cell context-dependent mechanisms
por: Manzotti, Gloria, et al.
Publicado: (2019) -
Autophagy and epithelial–mesenchymal transition: an intricate interplay in cancer
por: Gugnoni, Mila, et al.
Publicado: (2016) -
Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas
por: Zhang, Qing, et al.
Publicado: (2019) -
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
por: Wagner, Julia M., et al.
Publicado: (2010) -
Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
por: Ghazy, Ehab, et al.
Publicado: (2022)